Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Is Dapagliflozin Cost-effective for Treating Heart Failure?

Is Dapagliflozin Cost-effective for Treating Heart Failure? News & Analysis News From the JAMA Network Evidence for a Colorectal Cancer at 2 major trauma centers, 93 742 impaired effectiveness ratio (ICER), calculated as Screening Benefit After Age 75 Years driving convictions, and 24 million Uber incremental cost divided by incremental Colorectal cancer (CRC) screening with rides. The investigators compared traumas quality-adjusted life-years. lower endoscopy may be warranted for resulting from MVCs before and after Uber The analysis found that dapagliflozin had people older than 75 years and in good wasintroducedinHoustoninFebruary2014. an ICER of $83 650 per quality-adjusted health, a study in JAMA Oncology sug- life-year gained, an intermediate value ac- gested. The US Preventive Services Task cording to American College of Cardiology– Force currently recommends routine CRC American Heart Association benchmarks. Its screening until age 75 years, with individu- value was similar regardless of diabetes sta- alized decision-making for those aged 76 to tus and among patients with mild or mod- 85 years based on their screening history erate health impairment from heart failure. and overall health. But because clinical Dapagliflozin currently costs about $470 trials have excluded older individuals, it’s per month but the drug’s patent expired in unknown whether screening people 2020. If anticipated http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Is Dapagliflozin Cost-effective for Treating Heart Failure?

Slomski, Anita
JAMA , Volume 326 (5) – Aug 3, 2021
Download PDF
1 page

Is Dapagliflozin Cost-effective for Treating Heart Failure?

Abstract

News & Analysis News From the JAMA Network Evidence for a Colorectal Cancer at 2 major trauma centers, 93 742 impaired effectiveness ratio (ICER), calculated as Screening Benefit After Age 75 Years driving convictions, and 24 million Uber incremental cost divided by incremental Colorectal cancer (CRC) screening with rides. The investigators compared traumas quality-adjusted life-years. lower endoscopy may be warranted for resulting from MVCs before and after Uber The analysis found that...
Loading next page...
 
/lp/american-medical-association/is-dapagliflozin-cost-effective-for-treating-heart-failure-BkoaDwjFtu

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright 2021 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2021.12116
Publisher site
See Article on Publisher Site

Abstract

News & Analysis News From the JAMA Network Evidence for a Colorectal Cancer at 2 major trauma centers, 93 742 impaired effectiveness ratio (ICER), calculated as Screening Benefit After Age 75 Years driving convictions, and 24 million Uber incremental cost divided by incremental Colorectal cancer (CRC) screening with rides. The investigators compared traumas quality-adjusted life-years. lower endoscopy may be warranted for resulting from MVCs before and after Uber The analysis found that dapagliflozin had people older than 75 years and in good wasintroducedinHoustoninFebruary2014. an ICER of $83 650 per quality-adjusted health, a study in JAMA Oncology sug- life-year gained, an intermediate value ac- gested. The US Preventive Services Task cording to American College of Cardiology– Force currently recommends routine CRC American Heart Association benchmarks. Its screening until age 75 years, with individu- value was similar regardless of diabetes sta- alized decision-making for those aged 76 to tus and among patients with mild or mod- 85 years based on their screening history erate health impairment from heart failure. and overall health. But because clinical Dapagliflozin currently costs about $470 trials have excluded older individuals, it’s per month but the drug’s patent expired in unknown whether screening people 2020. If anticipated

Journal

JAMA – American Medical Association

Published: Aug 3, 2021

There are no references for this article.